当前位置: 首页 > 详情页

Inhibition of miR-128-3p by Tongxinluo Protects Human Cardiomyocytes from Ischemia/reperfusion Injury via Upregulation of p70s6k1/p-p70s6k1

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Chinese Acad Med Sci, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Dept Cardiol,State Key Lab Cardiovasc Dis, Beijing, Peoples R China; [2]Peking Union Med Coll, Beijing, Peoples R China; [3]Shandong Univ, Shandong Prov Hosp, Dept Cardiac Surg, Jinan, Shandong, Peoples R China; [4]Capital Med Univ, Beijing Friendship Hosp, Dept Cardiol, Beijing, Peoples R China; [5]Natl Key Lab Collateral Dis Res & Innovat Chinese, Shijiazhuang, Hebei, Peoples R China; [6]Capital Med Univ, Beijing Anzhen Hosp, Dept Surg, Intens Care Unit, Beijing, Peoples R China
出处:
ISSN:

关键词: myocardial reperfusion injury cardioprotection tongxinluo human cardiomyocytes apoptosis p70s6k1 miR-128-3p translational medicine

摘要:
Background and Aims: Tongxinluo (TXL) is a multifunctional traditional Chinese medicine that has been widely used to treat cardiovascular and cerebrovascular diseases. However, no studies have explored whether TXL can protect human cardiomyocytes (HCMs) from ischemia/reperfusion (I/R) injury. Reperfusion Injury Salvage Kinase (RISK) pathway activation was previously demonstrated to protect the hearts against I/R injury and it is generally activated via Akt or (and) Erk 1/2, and their common downstream protein, ribosomal protein S6 kinase (p70s6k). In addition, prior studies proved that TXL treatment of cells promoted secretion of VEGF, which could be stimulated by the increased phosphorylation of one p70s6k subtype, p70s6k1. Consequently, we hypothesized TXL could protect HCMs from I/R injury by activating p70s6k1 and investigated the underlying mechanism. Methods and Results: HCMs were exposed to hypoxia (18 h) and reoxygenation (2 h) (H/R), with or without TXL pretreatment. H/R reduced mitochondria' membrane potential, increased bax/bcl-2 ratios and cytochrome C levels and induced HCM apoptosis. TXL preconditioning reversed these H/R-induced changes in a dose-dependent manner and was most effective at 4001 mu g/mL. The anti-apoptotic effect of TXL was abrogated by rapamycin, an inhibitor of p70s6k. However, inhibitors of Erk1/2 (U0126) or Akt (LY294002) failed to inhibit the protective effect of TXL. TXL increased p70s6k1 expression and, thus, enhanced its phosphorylation. Furthermore, transfection of cardiomyocytes with siRNA to p70s6k1 abolished the protective effects of TXL. Among the micro-RNAs (miR-145-5p, miR-128-3p and miR-497-5p) previously reported to target p70s6k1, TXL downregulated miR-128-3p in HCMs during H/R, but had no effects on miR-145-5p and miR-497-5p. An in vivo study confirmed the role of the p70s6k1 pathway in the infarct-sparing effect of TXL, demonstrating that TXL decreased miR-128-3p levels in the rat myocardium during I/R. Transfection of HCMs with a hsa-miR-128-3p mimic eliminated the protective effects of TXL. Conclusions: The miR-128-3p/p70s6k1 signaling pathway is involved in protection by TXL against HCM apoptosis during H/R. Overexpression of p70s6k1 is, therefore, a potential new strategy for alleviating myocardial reperfusion injury.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2016]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2023]版:
大类 | 2 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2015]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2015版] 出版当年五年平均 出版前一年[2014版] 出版后一年[2016版]

第一作者:
第一作者机构: [1]Chinese Acad Med Sci, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Dept Cardiol,State Key Lab Cardiovasc Dis, Beijing, Peoples R China; [2]Peking Union Med Coll, Beijing, Peoples R China;
通讯作者:
通讯机构: [1]Chinese Acad Med Sci, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Dept Cardiol,State Key Lab Cardiovasc Dis, Beijing, Peoples R China; [2]Peking Union Med Coll, Beijing, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院